NeuroRPM
NeuroRPM is a Washington, D.C.-based digital health company building FDA-cleared, AI-enabled remote monitoring on Apple Watch for Parkinson's patients, serving neurology practices via prescription RPM and pharmaceutical sponsors through clinical trial outcome measures.
- Company typePrivate
- Founded2017
- HeadquartersWashington, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What NeuroRPM does
NeuroRPM is a Washington, D.C.-based digital health company founded in 2017 that develops FDA-cleared, AI-enabled remote monitoring technology for people living with neurodegenerative diseases, with a primary focus on Parkinson's disease. The company operates two product lines from a common sensor-and-algorithm platform: NeuroRPM-Rx, a prescription-based remote therapeutic monitoring (RPM) device delivered through neurology practices via the standard Apple Watch form factor, and NeuroRPM-CT, a clinical-trials platform that supplies continuous objective outcome measures to pharmaceutical and medical-device sponsors. The underlying technology uses proprietary algorithms to detect and quantify motor symptoms — including bradykinesia, tremor, and dyskinesia — from passively collected Apple Watch sensor data, and the platform is HIPAA-compliant with integrations into third-party health-data systems.
The product surface extends beyond core symptom tracking to include Companion Mode for caregiver data sharing, support for deep brain stimulation (DBS) programming workflows, and tools that surface longitudinal trends to clinicians, patients, and caregivers. NeuroRPM is a small private company (11–50 employees) operating exclusively in the U.S. market under FDA oversight, with its technology stack tightly coupled to Apple's hardware and software ecosystem.
NeuroRPM's business model combines recurring subscription-based remote physiological monitoring revenue from clinical care — distributed through physician prescription into neurology practices — with services revenue from clinical-trial sponsors running Parkinson's studies. Its go-to-market is effectively B2B2C: prescriptions originate from neurologists, while clinical-trial contracts are sourced directly from pharma and device sponsors, giving the company two distinct but complementary commercialization paths for the same underlying measurement technology.
NeuroRPM firmographics
Firmographics- Name
- NeuroRPM
- Legal name
- NeuroRPM Inc.
- Website
- https://neurorpm.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NeuroRPM is a Washington, D.C.-based digital health company building FDA-cleared, AI-enabled remote monitoring on Apple Watch for Parkinson's patients, serving neurology practices via prescription RPM and pharmaceutical sponsors through clinical trial outcome measures.
- Ownership category
- akta.pro rank
NeuroRPM industry classification
Industry- Product category
- Remote Patient Monitoring Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)
- akta.pro secondary industries
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE), Neurology Telemedicine Platforms (HLALAGAC), Movement Disorders (Parkinson’s, Tremor, Dystonia) (HLAKAIAC)
Keywords
Where NeuroRPM is headquartered
LocationHeadquarters
- HQ city
- Washington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NeuroRPM business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- NeuroRPM-Rx Subscription: Physician-prescribed remote patient monitoring subscription service for Parkinson's care. The platform supports RPM billing and reimbursement workflows for practices, indicating recurring revenue through healthcare provider prescriptions.
- NeuroRPM-CT Clinical Trial Services: Clinical trial monitoring services for pharmaceutical, medical device, and research partners providing objective symptom data and digital biomarkers for therapy development.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
NeuroRPM product offering
Product offeringCore offering
NeuroRPM develops an FDA-cleared, AI-enabled remote patient monitoring platform that uses Apple Watch sensors and a mobile application to detect and quantify Parkinson's motor symptoms (bradykinesia, tremor, dyskinesia). The company sells two product lines: NeuroRPM-Rx, a physician-prescribed subscription for clinical care, and NeuroRPM-CT, a clinical trial monitoring service for pharmaceutical and research partners. Both offerings include medication tracking, longitudinal symptom analytics, and HIPAA-compliant data handling.
Product overview
NeuroRPM offers two primary product lines: NeuroRPM-Rx for clinical care and NeuroRPM-CT for clinical trials. NeuroRPM-Rx is an FDA-cleared, AI-enabled, physician-prescribed remote patient monitoring platform that uses Apple Watch, mobile software, and advanced analytics to monitor Parkinson's motor symptoms while supporting medication tracking and clinical care decisions. NeuroRPM-CT serves pharmaceutical, medical device, and research partners with objective symptom monitoring for therapy development. Both products are supported by a mobile application featuring a Companion Mode for data sharing with caregivers, and built-in RPM workflows for reimbursement support.
Differentiator
Problem solved
Functional benefit
Products and services
- NeuroRPM-Rx AI-enabled, physician-prescribed remote patient monitoring platform for Parkinson's disease clinical care. Uses Apple Watch, mobile software, and advanced analytics to detect and visualize bradykinesia, tremor, and dyskinesia, while supporting medication tracking and integration of supplemental health data. Designed for neurology practices treating Parkinson's patients.
- NeuroRPM-CT Clinical trial support platform designed for pharmaceutical, medical device, and research partners. Provides objective Parkinson's motor symptom monitoring, medication context, baseline and longitudinal tracking, and real-world data to complement traditional clinical trial assessments for therapy development programs.
- NeuroRPM Mobile Application Companion iOS and Android mobile application that captures, uploads, transmits, displays, and accesses movement, health, and wellness information for individuals being evaluated for or diagnosed with Parkinson's disease, integrating with Apple Health and Google Fit.
Quantifiable outcome
- 6.5% increase in ON Time, 5.0% reduction in Tremor Detected, 3.5% reduction in Bradykinesia Detected, 1.0% reduction in Dyskinesia Detected following medication timing adjustment
- +1 more outcomes
Companies that use NeuroRPM
Customer profileSegments2 records
Ideal customer profiles2 records
NeuroRPM technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability4 records
Feature5 records
NeuroRPM partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ApplecoreNeuroRPM uses Apple Watch as the primary sensing device for collecting movement and motion data to monitor Parkinson's motor symptoms. The platform integrates with Apple Health data including heart rate, sleep, physical activity, and other health metrics collected by Apple Watch.
Scale indicators1 record
Expansion highlights5 records
NeuroRPM competitors and assessment
Company assessmentDirect peers
- Empatica: Maker of FDA-cleared wearable sensors (EpiMonitor) and AI analytics for continuous neurological monitoring, with FDA-cleared SaMD pathways overlapping NeuroRPM's regulatory and product positioning in neurology RPM.
- Great Lakes NeuroTechnologies: Developer of Kinesia and Kinesia One wearable systems for objective measurement of Parkinson's motor symptoms (tremor, bradykinesia, dyskinesia), directly competing with NeuroRPM in clinical-care and clinical-trial Parkinson's monitoring.
- Cala Health: Developer of Cala Trio, a wearable neuromodulation device for essential tremor and Parkinson's tremor therapy, with overlap in Parkinson's wearable monitoring and clinical-trial digital biomarker collaborations.
- Rune Labs: Rune Labs' Strive PD platform uses Apple Watch and wearable sensors to monitor Parkinson's motor symptoms and provides digital biomarkers to pharma for clinical trials—the closest direct competitor to NeuroRPM-Rx and NeuroRPM-CT, including a partnership with Roche.
- Biofourmis: AI-driven remote patient monitoring and digital therapeutics platform with neurology and chronic-disease RPM offerings, competing with NeuroRPM in physician-prescribed RPM reimbursement workflows and pharma-grade digital endpoints.
- Global Kinetics: Australian-based company behind the PKG (Personal KinetiGraph) wearable for continuous Parkinson's motor symptom monitoring, providing both clinical care and pharma-trial digital endpoints in the same category as NeuroRPM.
Others
- Sage Bionetworks: Non-profit running the Parkinson's mPower study on iPhone/Apple Watch, overlapping with NeuroRPM's use of Apple Watch for Parkinson's data collection and shaping industry expectations for digital Parkinson biomarkers.
- AbbVie: Marketer of Parkinson's therapies (e.g., Duopa, Vyalev) and a potential NeuroRPM-CT enterprise customer/partner for objective digital endpoints in Parkinson's drug development trials.
Broad incumbents
- Verily (Alphabet): Alphabet's health-technology subsidiary developing wearable and sensor-based digital biomarkers (historically including Parkinson's research with the Sync Project), operating as a larger incumbent in wearable-driven neurological monitoring.
- Medtronic: Manufacturer of Activa deep brain stimulation (DBS) systems for Parkinson's, with adjacent digital health efforts to objectively measure DBS outcomes—a clinical workflow that NeuroRPM specifically targets with its DBS programming evaluation feature.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NeuroRPM social profiles
Digital presenceNeuroRPM compliance and trust
Trust signalCompliance2 records
NeuroRPM financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroRPM leadership team
Management profileNumber of profiles
Profiles9 records
NeuroRPM funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroRPM M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroRPM
What does NeuroRPM do?
NeuroRPM develops an FDA-cleared, AI-enabled remote patient monitoring platform that uses Apple Watch sensors and a mobile application to detect and quantify Parkinson's motor symptoms (bradykinesia, tremor, dyskinesia). The company sells two product lines: NeuroRPM-Rx, a physician-prescribed subscription for clinical care, and NeuroRPM-CT, a clinical trial monitoring service for pharmaceutical and research partners. Both offerings include medication tracking, longitudinal symptom analytics, and HIPAA-compliant data handling.
Is NeuroRPM a public or private company?
NeuroRPM is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NeuroRPM founded?
NeuroRPM was founded in 2017. It employs 11 to 50 people.
Where is NeuroRPM based?
NeuroRPM is headquartered in Washington, United States, in the North America region.
How does NeuroRPM make money?
Two revenue lines are on record. NeuroRPM-Rx Subscription is the primary driver. The others are neuroRPM-CT Clinical Trial Services.
Who are NeuroRPM's main competitors?
Direct peers on record are Empatica, Great Lakes NeuroTechnologies, Cala Health, Rune Labs, Biofourmis and Global Kinetics. Others are Sage Bionetworks and AbbVie. Broad incumbents are Verily (Alphabet) and Medtronic.
Does NeuroRPM have an API?
No public API is recorded for NeuroRPM.
What industry is NeuroRPM in?
NeuroRPM's product category is Remote Patient Monitoring Software. Its primary akta.pro industry code is HLALAFAJ, Neurology RPM (epilepsy, Parkinson’s, MS monitoring), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.